Heidelberg, Germany – March 2012 – Heidelberg Engineering GmbH, the leading developer of laser diagnostics for ophthalmic applications, announced today that the United States Food and Drug Administration (FDA) has granted clearance for the new, SPECTRALIS® Anterior Segment Module (ASM).
The Anterior Segment Module provides high-resolution images of cornea, anterior chamber angle and sclera utilizing unique Heidelberg Noise Reduction™ technology for enhanced detail. Clinicians can assess both chamber angles at the same time using a 16mm-wide angle-to-angle OCT scan.
“The SPECTRALIS Anterior Segment Module paves the way towards digital gonioscopy”, said Sanjay Asrani, MD, Associate Professor of Ophthalmology, Duke University Eye Center. “Glaucoma surgeons will further benefit from the enhanced depth imaging (EDI) OCT capabilities of SPECTRALIS when assessing filtering blebs and anterior chamber angles.”
“The images from the anterior segment module have changed my understanding of the cornea and allowed me to see things more clearly”, stated Steven Safran, MD, ophthalmologist from Lawrenceville, NJ. “I believe that these images will change the way we evaluate and manage patients. Anterior segment surgeons will particularly benefit from having this technology available to them”, Dr. Safran added.
“The Anterior Segment Module broadens the range of applications of all SPECTRALIS SD-OCT Models”, noted Kester Nahen, PhD, VP Global Marketing and Business Development of Heidelberg Engineering. “The ASM adds to the list of modules such as BluePeak™ blue laser autofluorescence, wide field composite imaging as well as fluorescein and ICG video angiography available for SPECTRALIS devices”.